EPM
FLNA

Equitec Proprietary Markets’s Filana Therapeutics FLNA Stock Holding History

Equitec Proprietary Markets’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-300
Closed -$13K – 234
2022
Q3 		$13K Buy
+300
New +$8.1K ﹤0.01% 175
2021
Q4 		– Sell
-1,900
Closed -$118K – 449
2021
Q3 		$118K Buy
+1,900
New +$159K 0.02% 100

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Equitec Proprietary Markets's FLNA Position: Q4 2022 in Review

Equitec Proprietary Markets sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 300 shares — an estimated $13K sold.

Equitec Proprietary Markets first reported a position in FLNA in Q3 2021 and held it in 2 quarters. The position peaked at $118K in Q3 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

  • Equitec Proprietary Markets reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Equitec Proprietary Markets sold 300 Filana Therapeutics shares in Q4 2022, an estimated $13K.
  • Equitec Proprietary Markets first reported a position in Filana Therapeutics in Q3 2021 and held it in 2 quarters.
  • Equitec Proprietary Markets's Filana Therapeutics position peaked at $118K in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Equitec Proprietary Markets's 13F filing for Q4 2022, filed 31 Jan 2023.